The authors also report on the fact that BC200 inhibition is toxic to actively proliferating cells supporting the rationale of targeting this lncRNA in the treatment of not only breast cancer but also a broad spectrum of tumor types where BC200 is upregulated [81]. This evidence concerns the gene BCYRN1 and neoplasm.